Meihua Medical Files 6-K for 2023 Annual Report Translation

TL;DR

**Meihua just made their 2023 annual report translation available, standard stuff.**

AI Summary

Meihua International Medical Technologies Co., Ltd. filed a 6-K, indicating they are furnishing an English translation of their 2023 Annual Report on Form 20-F, which was filed with the SEC on April 26, 2024. This filing is routine and provides shareholders with access to the company's detailed financial and operational performance for the past year. For investors, this matters because it makes the comprehensive annual report, including audited financials and management's discussion, readily available for review, aiding in informed investment decisions.

Why It Matters

This filing makes Meihua's full 2023 annual financial and operational details accessible to investors, crucial for understanding the company's health and future prospects.

Risk Assessment

Risk Level: low — This is a routine administrative filing providing access to an already-filed annual report, posing no new direct financial risk.

Analyst Insight

Investors should review the full 2023 Annual Report on Form 20-F, now more easily accessible via this 6-K, to understand Meihua's financial performance and strategic direction.

Key Players & Entities

• Meihua International Medical Technologies Co., Ltd. (company) — the filer of the 6-K
• SEC (company) — the regulatory body with which the filing was made
• April 26, 2024 (date) — the date the Form 20-F was filed

FAQ

Key Financial Figures

• $0.0005 — inary shares of the Company, par value, $0.0005 per share, with the purchase price of $
• $0.38 — 5 per share, with the purchase price of $0.38 per share for the gross proceeds of $15
• $15.2 million — .38 per share for the gross proceeds of $15.2 million. On October 17, the Company issued 40,0
• $0.05 — dinary shares of the Company, par value $0.05 per share (“Shares”), with
• $11 — res”), with the purchase price of $11 per Share (the “December Offering
• $1,320,000 — Offering”), for gross proceeds of $1,320,000. The Company currently intends to use t

Filing Documents

• ea0269802-6k_meihua.htm (6-K) — 13KB
• ea026980201ex99-1_meihua.htm (EX-99.1) — 244KB
• 0001213900-25-122249.txt ( ) — 257KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 Commission file number 001-41291 Meihua International Medical Technologies Co., Ltd. (Translation of registrant’s name into English) 88 Tongda Road, Touqiao Town Guangling District, Yangzhou, 225000 People’s Republic of China (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Closing of a Private Placement As previously disclosed, Meihua International Medical Technologies Co., Ltd. (the “Company”) entered into a Securities Purchase Agreement with several “non-U.S. Persons” (the “October Purchasers”) as defined in Regulation S of the Securities Act of 1933, as amended (“the Securities Act”) on October 8, 2025 for a private placement (“October Offering”) of 40,000,000 ordinary shares of the Company, par value, $0.0005 per share, with the purchase price of $0.38 per share for the gross proceeds of $15.2 million. On October 17, the Company issued 40,000,000 ordinary shares to the October Purchasers and the October Offering was fully closed. Entry into a Material Agreement and Closing of a Private Placement On December 5, 2025, the Company entered into certain securities purchase agreement (the “SPA”) with certain “non-U.S. Persons” (the “December Purchasers”) as defined in Regulation S of the “Securities Act. Pursuant to the SPA, the Company agreed to sell up to an aggregate of 120,000 class A ordinary shares of the Company, par value $0.05 per share (“Shares”), with the purchase price of $11 per Share (the “December Offering”), for gross proceeds of $1,320,000. The Company currently intends to use the net proceeds from the December Offering for working capital and general corporate purposes. The parties to the SPA have each made customary representations, warranties and covenants, including, among other things, (a) the December Purchasers are “non-U.S. Persons” as defined in Regulation S and are acquiring the Shares for the purpose of investment, (b) the absence of any undisclosed material adverse effect, and (c) the absence of legal proceedings that affect the completion of the transaction contemplated by the SPA. On December 15, 2025, the December Offering was consummated, upon satisfaction of all of the closing conditions set forth in the SPA. The Shares were issued in reliance on the exemption from registration provided by Regulation S under the Securities Act. The Company currently has 697,914 issued and outstanding class A ordinary shares. The form of the SPA is filed as Exhibit 99.1, and such document is incorporated herein by reference. The foregoing is only a brief description of the material terms of the SPA and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to such exhibit. Exhibits Exhibit No. Description 99.1 Form of the Securities Purchase Agreement by and among the Company and the December Purchasers 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Meihua International Medical Technologies Co., Ltd. By: /s/ Leyi Lee Name: Leyi Lee Title: Chief Executive Officer Date: December 16, 2025 2

View Full Filing

View this 6-K filing on SEC EDGAR